Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis.
J Lipid Res
; 64(6): 100375, 2023 06.
Article
en En
| MEDLINE
| ID: mdl-37075981
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality. Prognostic biomarkers to identify rapid progressors are urgently needed to improve patient management. Since the lysophosphatidic acid (LPA) pathway has been implicated in lung fibrosis in preclinical models and identified as a potential therapeutic target, we aimed to investigate if bioactive lipid LPA species could be prognostic biomarkers that predict IPF disease progression. LPAs and lipidomics were measured in baseline placebo plasma of a randomized IPF-controlled trial. The association of lipids with disease progression indices were assessed using statistical models. Compared to healthy, IPF patients had significantly higher levels of five LPAs (LPA160, 161, 181, 182, 204) and reduced levels of two triglycerides species (TAG484-FA120, -FA182) (false discovery rate < 0.05, fold change > 2). Patients with higher levels of LPAs had greater declines in diffusion capacity of carbon monoxide over 52 weeks (P < 0.01); additionally, LPA204-high (≥median) patients had earlier time to exacerbation compared to LPA204-low (Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis Pulmonar Idiopática
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
J Lipid Res
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos